Human Cardiolipin IgM ELISA kit

CAT#: EA100916

Human Cardiolipin IgM ELISA kit

Specifications

Product Data

• Format: 8x12 divisible strips
• Assay Type: Solid Phase Sandwich ELISA
• Assay Length: 3 hours
• Signal: Colorimetric
• Sample Type: Serum
• Sample Volume: 10 µl/well
• Specificity: This kit is used for quantitative detection human Cardiolipin IgM
• Reactivities: Human
• Cross Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Interference: No significant interference observed with available related molecules.
• Components:
  • 1. Microwell coated with Cardiolipin antigen: 12x8x1
  • 2. Sample Diluent: 1 bottle (ready to use): 22 ml
  • 3. Calibrator: 1 Vial (ready to use): 1ml
  • 4. Positive Control: 1 vial (ready to use): 1ml
  • 5. Negative Control: 1 vial (ready to use): 1ml
  • 6. Enzyme conjugate: 1 bottle (ready to use): 12ml
  • 7. TMB Substrate: 1 bottle (ready to use): 12ml
  • 8. Stop Solution: 1 bottle (ready to use): 12ml
  • 9. Wash concentrate 20X: 1 bottle: 25ml
• Background: Measurement of IgG, IgM and IgA cardiolipin autoantibodies (aCL) by EIA is the standard procedure for the detection of antiphospholipid antibodies (aPL) in patients with suspected antiphospholipid syndrome (APS). High aCL concentrations are associated with increased risk of venous and arterial thrombosis, recurrent pregnancy loss and thrombocytopenia. Patients with the anti-cardiolipin syndrome have one of the above clinical features and have antibodies to cardiolipin and/or a positive lupus anticoagulant test. The antibodies present to cardiolipin may be of the IgG, IgA, IgM isotypes. Testing for the various antibody isotypes to cardiolipin aids in diagnosis of the anti-phospholipid syndrome in patients with SLE or lupus-like disorders. Binding of aCL to CL in patients with autoimmune diseases is dependent on the presence of the cofactor beta-2-glycoprotein I (beta2-GPI); this binding is independent of beta-2-GPI in patients with infectious diseases (e.g., syphilis, tuberculosis). Recognition of the role of beta-2- GPI in the binding of aCL led to development of assay for direct measurement of beta-2-GPI autoantibodies using beta-2-GPI as antigen, allowing a clear distinction between beta-2-GPI autoantibodies and those that bind to CL alone.